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Airway remodeling in asthma is a result of persistent inflammation and epithelial damage in response to repetitive 
injury. Recent studies have identified several important mediators associated with airway remodeling in asthma, including 
transforming growth factor-β, interleukin (IL)-5, basic fibroblast growth factor, vascular endothelial growth factor, LIGHT, 
tumor necrosis factor (TNF)-α, thymic stromal lymphopoietin, IL-33, and IL-25. In addition, the epithelium mesenchymal 
transformation (EMT) induced by environmental factors may play an important role in initiating this process. Diagnostic 
methods using sputum and blood biomarkers as well as radiological interventions have been developed to distinguish 
between asthma sub-phenotypes. Human clinical trials have been conducted to evaluate biological therapies that target 
individual inflammatory cells or mediators including anti IgE, anti IL-5, and anti TNF-α. Furthermore, new drugs such 
as c-kit/platelet-derived growth factor receptor kinase inhibitors, endothelin-1 receptor antagonists, calcium channel 
inhibitors, and HMG-CoA reductase inhibitors have been developed to treat asthma-related symptoms. In addition to 
targeting specific inflammatory cells or mediators, preventing the initiation of EMT may be important for targeted treatment. 
Interestingly, bronchial thermoplasty reduces smooth muscle mass in patients with severe asthma and improves 
asthma-specific quality of life, particularly by reducing severe exacerbation and healthcare use. A wide range of different 
therapeutic approaches has been developed to address the immunological processes of asthma and to treat this complex 
chronic illness. An important future direction may be to investigate the role of mediators involved in the development of 
airway remodeling to enhance asthma therapy. 
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INTRODUCTION 
Asthma is a chronic inflammatory disease of the airway 
that is characterized by the presence of inflammatory cells 
and structural changes that are referred to as “airway 
remodeling.” Classically, airway remodeling in patients 
with asthma constitutes subepithelial fibrosis, increased 
deposition of extracellular matrix protein, goblet cell hy-
perplasia and mucus gland hypertrophy, smooth muscle 
hypertrophy and hyperplasia, and epithelial damage [1-3]. 
Candidate cells involved in airway remodeling are eosino-
phils, T-lymphocytes, mast cells, epithelia, macrophages, 
airway smooth muscle (ASM) cells, and fibroblasts. Im-
mune cells provide mediators that are involved in the 
process of airway remodeling [4-6]. Several mediators 
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endothelial growth factor (VEGF), ADAM metallopepti-
dase domain 33 (ADAM-33), matrix metalloproteinase-9 
(MMP-9), and Th2 cytokines (interleukin [IL]-5, IL-13, 
IL-4, and IL-9) are linked to remodeling [4-6]. Additional 
mediators have recently been identified including LIGHT 
(TNFSF14), tumor necrosis factor (TNF)-α, and basic fi-
broblast growth factor (bFGF) [7-10]. Epithelial cells are 
also important in the initiation of allergic inflammation. 
Epithelial injury results in the persistent activation of epi-
thelial mesenchymal transforming unit (EMTU), which 
promotes airway remodeling, leading to persistent asthma 
[10,11]. Epithelial injury increases the expression of thymic 
stromal lymphopoietin (TSLP), IL-33, and IL-25, which 
induce Th2 memory cell expansion and cytokine secre-
tion [12]. Clinicians seek additional options other than the 
currently available conventional treatments to improve 
the condition of patients with severe asthma and to spare 
systemic corticosteroid administration. This review pres-
ents recent advances in the mechanism, diagnosis, and 
treatment of asthma, focusing on the use of mediators for 
airway remodeling therapy, as well as procedures that as-
sess asthma severity. Animal research and human studies 
have enabled clinicians to better evaluate the extent of air-
way remodeling and to design specific treatment strategies 
appropriate for each patient.
MECHANISMS OF AIRWAY REMODELING: 
A LINK BETWEEN CELLS AND MEDIA-
TORS
Animal studies using models of airway remodeling and 
human studies both support the finding that immune or 
inflammatory cells and mediators are important in the 
pathogenesis of airway remodeling (Fig. 1). For example, 
recent studies have demonstrated that environmental fac-
tors cause a defect in the epithelia, inducing an innate im-
mune response by activating dendritic cells and Th2 mem-
ory cells to release mediators linked to remodeling [13]. 
In addition, eosinophils are immune cells that express 
TGF-β, which acts as a key mediator during airway remod-
eling. Studies using anti IL-5 antibody to deplete eosino-
phils have reported a link between eosinophilic depletion 
and decreased TGF-β expression. Other cell types such 
as bronchial epithelial cells and macrophages may also 
express TGF-β in the lung. It is essential to understand the 
link between cells and mediators during remodeling to en-
hance current biological therapies for asthma.
Eosinophil related cytokines: IL-5,CCR-3, Siglec-
8(F) 
Allergen-induced murine models of airway remodeling 
have highlighted the importance of eosinophils during air-
way remodeling. IL-5 transgenic mice exhibit an increase 
in eosinophils in the lung, accumulation of peribronchial 
eosinophils, goblet cell hyperplasia, epithelial hypertrophy, 
and focal collagen deposition. They also show airway hy-
per-responsiveness (AHR) to methacholine in the absence 
of an aerosolized antigen challenge [4]. IL-5, chemokine 
receptor (CCR)-3, and siglec-8(F) are critical molecules 
associated with eosinophilic trafficking in target organs.
IL-5
IL-5 is a key cytokine that regulates the proliferation 
and differentiation of eosinophils, as well as the trafficking 
of eosinophils from the bone marrow to the lung [14,15]. A 
remarkable reduction in TGF-β-expressing eosinophils oc-
curs in the remodeled airways of IL-5-deficient mice. Anti 
IL-5 treatment significantly reduces levels of bronchoalve-
olar lavage (BAL) eosinophils and remodeling, as assessed 
by reduced deposition of the extracellular matrix-associat-
ed remodeling proteins procollagen and tenascin [16]. Fur-
thermore, the anti IL-5 antibody mepolizumab decreases 
airway thickness and wall area in patients with refractory 
asthma [17]. Several anti IL-5 antibodies including me-
polizumab, reslizumab, and enralizumab (MEDI563) are 
now in clinical trials. However, blocking IL-5 alone only 
reduces 50–60% of tissue eosinophils; therefore, addi-
tional blocking of eosinophil trafficking may be required 
to completely block eosinophils. 
CCR-3
CCR-3 is a chemokine receptor expressed by eosinophils 
that mediates chemotaxis in response to chemokines in-
cluding eotaxin and RANTES. CCR-3-deficient mice and 
eotaxin-deficient mice show decreased levels of airway 
eosinophilia and mucus production [6]. Reduced subepi-
thelial fibrosis and goblet cell hyperplasia are observed 
in a mouse model of airway remodeling subjected to low-
molecular-weight CCR-3 antagonists [18]. A recent study 
administered a CCR-3 receptor antagonist (Ki19003) to an 
ovalbumin (OVA)-induced asthma model and found that Cho jy. Recent advances in airway remodeling    369
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Ki19003 inhibits airway eosinophilic inflammation and 
peribonchial fibrosis, and increases levels of TGF-β in BAL 
[19]. An oral CCR-3 antagonist (GW766944) is now on 
clinical trial (ClinicalTrials.gov NCT01160224). 
Siglec-8
Siglec-8 is highly expressed on human eosinophils and 
is a candidate molecule that may be targeted to alleviate 
eosinophilic inflammation. The siglec-8 receptor cross-
links with eosinophils to induce an apoptotic signal. 
Mouse siglec-F shares many properties with human si-
glec-8, including predominant expression on eosinophils 
and unique ligand specificity. Thus, mouse siglec-F has 
provided insight into the potential role of siglec-8 in hu-
man allergic disease [20,21]. A recent study used a chronic 
OVA-challenged murine model to demonstrate that 
siglec-F plays a role in airway remodeling by modulating 
eosinophilic apoptosis in lung and bone marrow; further-
more, treatments using anti siglec-F antibody significantly 
reduced the number of peribronchial TGF-β-expressing 
eosinophils and the level of peribronchial fibrosis [22]. A 
significant increase in mucus production, peribronchial 
fibrosis, and smooth muscle thickness occurs in chronic   
OVA-challenged mice deficient in siglec-F; IL-4 or IL-13 
significantly increase the level of siglec-F ligand expression 
in bronchial epithelium. Thus, human siglec-8 may be an 
additional target to modulate eosinophil recruiting during 
human airway remodeling [23]. 
LIGHT (TNFSF14; homologous to lymphotoxin): 
lymphocytes
The TNF superfamily (TNFSFs) consists of many 
membrane-bound and soluble proteins that act as key 
mediators of asthmatic inflammation such as the OX40 
ligand (TNFSF4) and TNF itself. The TNF family ligand 
LIGHT (TNFSF14) is expressed on B and T cells but not 
on macrophages and granulocytes [7]. LIGHT binds the 
herpesvirus entry mediator (TNFRSF14). It also acts as a 
ligand for membrane lymphotoxin (LTαβ). Lymphotoxin 
β receptor (LTβR) is strongly expressed on macrophages 
[7]. A recent study reported an increase in soluble LIGHT 
in the sputum of patients with asthma, highlighting the 
role of LIGHT (TNFSF14) in asthma. LIGHT levels in 
BAL fluid are higher in patients with pulmonary fibro-
sis [24]. Pharmacological inhibition of LIGHT using the 
IgG Fc domain and LTβR reduces lung fibrosis, smooth 
Figure 1. Inflammatory cells and mediators related to induction of airway remodeling and biological therapy targeting specific cells 
and mediators. Airway remodeling is a result of persistent inflammation and epithelial damage by repetitive injuries. Several important 
mediators including transforming growth factor (TGF)-β, interleukin (IL)-5, basic fibroblast growth factor (bFGF), vascular endothelial 
growth factor (VEGF), LIGHT, tumor necrosis factor (TNF)-α, thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 are associated 
with airway remodeling in asthma. Biological therapy targeting specific cells or mediators are now in clinical trial. CCR-3, chemokine 
receptor type 3; MMP, matrix metalloproteinase. 
aBronchoscopic procedure which delivers thermal energy to the airway wall to reduce 
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muscle hyperplasia, and AHR in mouse models of chronic 
asthma. LIGHT-deficient mice also show a similar disrup-
tion of fibrosis and smooth muscle hyperplasia, whereas 
exogenous administration of LIGHT induces fibrosis and 
smooth muscle hyperplasia. Thus, LIGHT may be a poten-
tial target to prevent and/or treat airway remodeling [24].
Mediators from multiple cell types: TGF-β, bFGF, 
VEGF, TNF-α, MMPs
TGF-β 
TGF-β is a profibrotic cytokine, another key airway re-
modeling mediator in asthma [25]. TGF-β is produced by 
several cell types, including epithelial cells, eosinophils, 
macrophages, and fibroblasts. It is involved in epithelial 
changes, subepithelial fibrosis, ASM remodeling, mi-
crovascular changes, and increased mucus production. 
Subepithelial fibrosis is mediated by the induction of 
TGF-β expression and the consequent activation of myo-
fibroblasts, which produce extracellular matrix proteins 
such as collagen and fibronectin. TGF-β enhances the 
migration of ASM and produces antiapoptotic effects that 
stimulate ASM proliferation. Microvascular congestion 
by secretion of proangiogenic factors such as VEGF and 
upregulation of mucus production may be induced by 
TGF-β stimulation [26,27]. Furthermore, TGF-β decreases 
the production of enzymes that degrade the extracellular 
matrix (collagenase) and increases the production of pro-
teins that inhibit enzymes that degrade the extracellular 
matrix (tissue inhibitor of metalloprotease, TIMP) [28]. 
Smad3 is a TGF-β signaling molecule. Smad3-deficient 
mice chronically challenged with allergen show reduced 
numbers of peribronchial myofibroblasts and decreased 
peribronchial fibrosis [29]. Neutralizing TGF-β expression 
either by blocking TGF-β signaling in the Smad-3 pathway 
or administering anti activin-A significantly reduces peri-
bronchial fibrosis, ASM proliferation, and mucus produc-
tion [30]. Increased levels of TGF-β have been reported 
in BAL and biopsy specimens of patients with asthma 
[31,32]. TGF-β expression correlates with the degree of 
subepithelial fibrosis. Levels of TGF-β increase signifi-
cantly in patients with severe asthma and prominent air-
way eosinophilic inflammation. TGF-β levels in the lungs 
of patients with asthma decrease by depleting eosinophils 
through anti IL-5 antibody treatment. Surprisingly, very 
few preclinical experiments using TGF-β inhibitors have 
been published [33]. Currently, a monoclonal anti TGF-β 
antibody (GC1008) is being tested in a phase I study to 
treat idiopathic pulmonary fibrosis (NCT00125385). 
bFGF
bFGF is a cytokine that is mitogenic to fibroblasts and 
smooth muscle [34-36], and has proangiogenic properties 
related to angiogenesis during airway remodeling. Cellular 
sources of bFGF include macrophages, endothelial cells, 
mast cells, epithelial cells, and fibroblasts [37]. bFGF binds 
to 1-4 high-affinity FGF receptors [38]. A study using 
chronic OVA-induced airway remodeling demonstrated 
that bFGF is expressed by peribronchial macrophages 
and epithelium. Furthermore, bFGF and TGF-β1 are co-
expressed on peribronchial macrophages, implying an as-
sociation between these molecules during airway remod-
eling. The synergistic effects of bFGF and TGF-β1 have 
also been found in other cell types [39]. Mast cell-derived 
activin A, an activator of Smad2/3/4 and a potent inducer 
of human ASM cell proliferation, could be the main TGF-β 
superfamily member that synergizes with bFGF to induce 
ASM hyperplasia [40]. Interestingly, bFGF administration 
reduces airway inflammation and AHR in an acute OVA-
challenged murine model of asthma [41]. Clinical studies 
have found an increase in the presence of bFGF immu-
noreactive cells and levels of bFGF protein in the sputum 
and BAL fluid of patients with asthma compared to non-
asthmatic controls [42,43]. Further studies are needed to 
clarify the role of bFGF during airway remodeling.
VEGF
VEGF is a critical multifunctional angiogenic regulator 
that stimulates epithelial cell proliferation, blood vessel 
formation, and endothelial cell survival [44]. VEGF has 
been postulated to contribute to asthmatic tissue edema 
through its effects on vascular permeability [45,46]. Lung-
targeted VEGF165 transgenic mice have an asthma-like 
phenotype that includes not only vascular remodeling but 
also inflammation, edema, mucus metaplasia, myocyte 
hyperplasia, and AHR [47]. Recent studies that investigat-
ed the mechanism of VEGF in a murine model of asthma 
have shown that nitric oxide is an important mediator of 
the extravascular VEGF remodeling effects [48]. VEGF 
is elevated in induced sputum, BAL fluid, and bronchial 
biopsies of patients with asthma [49]. A comparative study 
of two angiogenic factors, VEGF and angiogenin, dem-Cho jy. Recent advances in airway remodeling    371
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onstrated that children with asthma have significantly 
higher levels of VEGF and angiogenin than non-asthmatic 
children, and that the increased levels of VEGF and angio-
genin are correlated to asthma severity [50]. In addition, 
sputum VEGF levels in smoking patients with asthma are 
significantly lower than those in nonsmoking patients with 
asthma but remain higher than those in control subjects 
[51]. Based on these findings, VEGF may be involved in 
vascular and airway remodeling in patients with asthma. 
TNF-α
TNF-α is a pro-inflammatory cytokine that increases 
in the airways of patients with asthma. TNF was initially 
believed to be produced primarily by macrophages but has 
been shown to be expressed by a broad range of cell types 
including mast cells and eosinophils [52,53]. Allergen-
challenged TNFp55/p75 receptor-deficient mice have sig-
nificantly reduced levels of peribronchial eosinophils and 
fibrosis [8]. Studies on mast cell function-deficient mice 
have demonstrated that mast cells play an important role 
in eosinophilic lung inflammation, cytokine production, 
AHR, and production of adhesion molecules, including in-
tercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion protein 1 (VCAM-1) by liberating TNF-α [53,54]. 
Increased TNF-α levels in BAL are associated with in-
creased levels of remodeling in patients with asthma. 
Inhibiting TNF-α reduces asthma exacerbation, further 
suggesting that TNF-α may be related to airway remodel-
ing. A study using etanercept, a fusion protein consisting 
of the type II TNF receptor that binds both TNF-α and β, 
found that patients with refractory asthma have increased 
expression of membrane-bound TNF-α, TNF-α receptor 
1, and TNF-α converting enzyme [55]. These findings col-
lectively suggest that TNF-α may be involved in asthma 
airway remodeling through eosinophils and mast cells. 
 
MMP-9 and ADAM-33
MMP-9 belongs to a family of extracellular proteases 
that are responsible for degrading the extracellular matrix 
during tissue remodeling. An example of MMP-9 activity 
is the broad-spectrum MMPI inhibitor R 94128, which 
reduces the development of allergic airway inflammation 
[56]. An MMP-9-deficient murine asthma model showed 
reduced peribronchial fibrosis and total lung collagen com-
pared to wild-type mice, yet no difference was detected 
in mucus expression, smooth muscle thickness, or airway 
responsiveness [57]. Moreover, human studies have shown 
that levels of MMP-9 (gelatinase B) increase significantly 
in BAL fluid, blood, and sputum of patients with allergic 
asthma [58]. Thus, therapies targeting MMP-9 may not 
only decrease airway inflammation but also reduce the 
levels of peribronchial fibrosis during airway remodeling.
ADAM-33 is a disintegrin and a metalloprotease ex-
pressed in patients with asthma [59]. Allergen-challenged 
ADAM-33-deficient mice show no significant differences 
in airway hyper-reactivity, IgE production, mucus meta-
plasia, or airway inflammation compared to wild type 
mice [1]. However, ADAM-33 mRNA expression is signifi-
cantly enhanced in the lung tissue of OVA-challenged mice 
[60]. A genetic polymorphism in ADAM-33 is a novel asth-
ma-associated gene, which results in an accelerated de-
cline in lung function over time. Furthermore, ADAM-33 
mRNA expression is higher in patients with severe asthma 
than in patients with mild asthma or without asthma [61]. 
ADAM-33 may be a key molecule that contributes to ASM 
and vascular remodeling.
Epithelium related mediators: TSLP, IL-25, IL-33
The epithelium plays an important role initiating aller-
gic inflammation. Epithelial injury results in persistent ac-
tivation of the EMTU [11], an attenuated fibroblast sheath 
that is in contact with bronchial epithelium and coordi-
nates airway remodeling following epithelial injury. Epi-
thelial injury caused by viruses, fungus, double-stranded 
RNA, and protease allergens increase TSLP, IL-33, and IL-
25 expression, which induces Th2 memory cell expansion 
and Th2 cytokine secretion [62]. 
TSLP
TSLP, a distant paralog of IL-7, is a type I cytokine and a 
member of the IL-2 cytokine family. TSLP is expressed by 
the epithelium, keratinocytes, macrophages, neutrophils, 
and mast cells. A recent study demonstrated that TNF-α 
induces TSLP in human ASM as well [63]. Transgenic mice 
that overexpress TSLP show increased levels of allergic 
inflammation similar to that in human asthma. Allergen-
challenged mice deficient in TSLP-receptor knockdown 
exhibit suppressed airway inflammation [64]. Zhang et al. 
[65] demonstrated that a soluble TSLP antagonist, TSLPR-
immunoglobulin, reduces the severity of allergic disease. 
House dust mite protease upregulates epidermal growth 
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and thymus and activates activation-regulated chemo-
kine and TSLP, which results in epithelium mesenchymal 
transformation (EMT) and, ultimately, airway remodeling 
[66,67]. In humans, increased levels of TSLP have been 
found in airway epithelium and other inflammatory cells 
of patients suffering from asthma and chronic obstructive 
pulmonary disorder [68,69]. TSLP expression in the air-
ways of patients with asthma is correlated with expression 
of Th2 cytokines and disease severity [70]. Thus, TSLP 
may play an important role in asthma airway remodeling 
by inducing EMT. 
IL-25 (IL-17E)
IL-25 (IL-17E) is a member of the IL-17 cytokine family 
that evokes TH2 cell-mediated immunity to parasitic in-
fections [71]. Its upregulation induces a robust expansion 
of TH2 memory cells by TSLP-activated dendritic cells [12]. 
IL-25 is not only expressed by lung epithelial cells but also 
by mast cells, eosinophils, and basophils and is considered 
part of the innate immune response [72,73]. Moreover, IL-
25R is also found on eosinophils, monocytes, ASM cells, 
and fibroblasts [12]; the expression of IL-25R on these 
inflammatory and structural cells suggests that it may be 
involved in airway remodeling. Transgenic overexpression 
of IL-25 leads to mucus production and airway infiltration 
by macrophages and eosinophils, whereas IL-25 blockade 
reduces airway inflammation and TH2 cytokine produc-
tion in a murine allergen-induced asthma model [72]. 
Furthermore, studies on IL-25-deficient mice were unable 
to induce a Th2 response upon Trichuris muris infection, 
and repeated nasal administration of IL-25 resulted in 
IL-5 and IL-13 expression in the lung [71,74]. In human 
studies, IL-25+, IL-25R, and CD31+/IL-25R+ cells are 
significantly elevated in the bronchial mucosa of patients 
with asthma, and the number of IL-25+ cells correlate 
inversely with FEV1, suggesting that IL-25 may contribute 
to angiogenesis by increasing VEGF/VEGF receptor ex-
pression in patients with asthma [75]. Taken together, IL-
25 may be involved in airway remodeling by inducing Th2 
cytokines such as IL-5 and IL-13 or by directly inducing 
angiogenesis. 
IL-33 
IL-33 is a member of the IL-1 family, associated with 
promoting a systemic Th2 response [76]. IL-33 expression 
occurs in a variety of cells, including epithelial cells, fibro-
blasts, endothelial cells, cardiac myocytes, keratinocytes, 
adipocytes, and alveolar macrophages [77-79]. The IL-
33 receptor (ST2) is also expressed on Th2 cells, innate 
lymphoid cells, mast cells, eosinophils, macrophages, and 
basophils. IL-33 stimulates Th2 cytokine secretion such as 
IL-5 and IL-13 from these cells types. In animal studies, 
administering IL-33 into the lung induces AHR and gob-
let cell hyperplasia and upregulates IL-5, IL-4, and IL-13 
in the lung [80,81]. IL-33 transgenic mice spontaneously 
develop eosinophilic inflammation [82]. Administering 
the anti IL-33 also abrogates Th2 cytokine secretion and 
eosinophilic recruitment [83]. IL-33-deficient mice are 
resistant to allergen-induced AHR [84]. The subcutaneous 
administration of IL-33 results in ST2-dependent recruit-
ment of eosinophils, CD3+ lymphocytes, F4/80 macro-
phages, increased IL-13 mRNA, and the development of 
cutaneous fibrosis [85]. In human studies, IL-33 expres-
sion in epithelial cells increases in patients with asthma 
compared to healthy individuals and increases more dra-
matically in patients with severe asthma [86]. IL-33 and 
ST2 gene polymorphisms have been linked to asthma [87]. 
Higher IL-33 expression is also found in other allergic 
diseases, including allergic conjunctivitis, rhinitis, and 
atopic dermatitis. It is difficult to make a direct correlation 
between IL-33 and airway remodeling. However, previous 
findings suggest that IL-33 may be an important factor 
during airway remodeling.
ASSESSMENT OF AIRWAY REMODELING
Non-invasive methods such as the pulmonary func-
tion test (PFT), high-resolution computed tomography 
(HRCT), and magnetic resonance image (MRI) are uti-
lized to measure airway function and the pathology of the 
lung to assess the degree of airway remodeling. Invasive 
methods such as sputum induction are utilized for a closer 
examination of airway remodeling to assess inflammatory 
cells, determine blood eosinophil numbers, and measure 
levels of inflammatory mediators. Furthermore, broncho-
scopic biopsy or BAL, and endobronchial ultrasonography 
(EBUS) may also be used to assess the level of airway re-
modeling (Fig. 2). 
Non-invasive methods
PFTs using methacholine or exercise provocation have Cho jy. Recent advances in airway remodeling    373
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been a traditional diagnostic tool for assessing AHR in 
patients with asthma. Studies have been conducted to 
evaluate the efficacy of PFT as an airway-remodeling as-
sessment method. A longitudinal population study of 
asthma from childhood to adulthood demonstrated that 
a low postbronchodilator ratio of FEV1 to vital capacity is 
useful as an airway remodeling marker, which, in turn, 
was associated with an accelerated decline in lung func-
tion and reversibility [88]. Many studies have shown that 
computed tomography scans may be useful for assessing 
airway remodeling by measuring bronchial wall thickness 
[89]. A recent retrospective quantitative analysis of HRCT 
scans in 99 patients with severe asthma versus 16 healthy 
controls demonstrated that the right upper apical segmen-
tal bronchus (RB1) wall area (WA) % increases in patients 
with severe asthma, whereas the ratio of lumen area to 
body surface area decreases. Moreover, increased WA% of 
RB1 in patients with severe asthma was associated with 
impaired lung function and neutrophilic inflammation in 
a sputum study [90]. Quantitative densitometry of com-
puted tomography (CT) images serves as an additional tool 
for non-invasively studying airway remodeling in patients 
with asthma [91]. Hyperpolarized gas MRIs of patients 
with asthma commonly exhibit ventilation defects; the   
size and the extent of the ventilation defects are correlated 
with the severity of regional airway closure and narrow-
ing. A recent study demonstrated that the ventilation de-
fects on MRI images of patients with moderate to severe 
asthma are significantly greater than those of patients 
with mild asthma [92]. Another study using hyperpolar-
ized helium-3 MRI found a moderate correlation between 
the number of ventilation defects and predicted FEV1%. 
However, no significant correlation was found between the 
total number of ventilation defects and whole lung inflam-
mation markers in BAL analysis [93]. CT and MRI have 
been and will continue to be instrumental for assessing 
airway remodeling to provide treatments for asthma in the 
future. 
Sputum induction is another useful tool that assesses 
the degree of inflammation by measuring the levels of me-
diators in patients with asthma. Because the levels of lung 
inflammation correlate with airway remodeling severity, 
the absolute numbers of inflammatory cells, including 
eosinophils, neutrophils, and macrophages, are used to 
help assess the development of airway remodeling. In a 
study that examined osteopontin in patients with severe 
refractory asthma, the levels of sputum supernatant cyste-
inyl leukotrienes IL-13, TGF-β1, and eosinophilic cationic 
Figure 2. Evaluation and treatment approach during asthmatic airway remodeling. Non-invasive methods such as the pulmonary func-
tion test (PFT), high-resolution computed tomography (HRCT), and magnetic resonance imaging (MRI) are utilized first to assess the 
degree of airway remodeling. Invasive methods such as sputum induction for inflammatory cells and biological markers, blood eosino-
phils and IgE, bronchoscopic biopsy or bronchoalveolar lavage, and endobronchial ultrasonography may be applied for a more detailed 
determination of airway remodeling. Additional treatment including biological therapy and bronchial thermoplasty can then be used as 
a more mechanical approach to treatment based on asthma subtype. CT, computed tomography; CS, corticosteroid; LT, leukotriene; IL, 
interleukin; TNF, tumor necrosis factor. 
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protein (ECP) were higher in patients with severe asthma 
than in healthy subjects [94]. Another study, which fo-
cused on persistent remodeling and eosinophil activation, 
showed that histamine and ECP levels from patients with 
asthma in complete remission are significantly lower than 
those in patients who continue to suffer from severe asth-
ma [95]. A study of the effects of formoterol-budesonide on 
airway remodeling in patients with asthma demonstrated 
a significant decrease in the levels of MMP-9, TIMP-1, and 
TGF-β1 after treatment [96]. 
Blood eosinophil number, serum IgE level, and other 
biomarkers may also indicate the level of airway remod-
eling. A study of occupational asthma biomarkers dem-
onstrated that serum VEGF, MMP-9, and other markers 
could be measured in three diisocyanate-induced patients 
with occupational asthma (TDI-OA) and found that se-
rum MMP-9 level is elevated in patients with TDI-OA 
compared to that in healthy control subjects [97]. Thus, 
measuring sputum and serum eosinophil biomarker levels 
could be useful for assessing the degree of asthmatic air-
way remodeling. 
Invasive methods
EBUS has been used to assess bronchial wall remodel-
ing in patients with asthma [98]. This method correlates 
asthma severity parameters to bronchial wall layers. Fur-
thermore, a bronchial biopsy with specific immunohisto-
chemical stains and analysis of BAL fluid by bronchoscopy 
can help determine the degree of remodeling and inflam-
matory cell involvement. 
RECENT TREATMENT STRATEGIES FOR 
AIRWAY REMODELING
Conventional treatments do not adequately control 
some severe cases of asthma. This has been a major clini-
cal challenge, which is becoming an important healthcare 
issue. In the last decade, this dilemma has fostered the 
development of several biological and pharmacological 
agents to provide possible mechanical treatments for ASM. 
Phenotyping each patient will be very important to specifi-
cally tailor treatment for patients with severe asthma. 
Biologic therapy (Table 1)
Monoclonal antibodies against IgE or cytokines includ-
ing anti IgE (omalizumab), anti IL-5 (mepilozumab), and 
anti TNF-α (etanercept) have been investigated in patients 
with asthma. Other candidates for antibody treatment 
include anti IL-4, anti IL-4/13, anti IL-9, anti CD25, and 
anti TSLP, which are currently under clinical trial.
Anti IgE antibody (omalizumab, Xolair)
Omalizumab and Xolair are humanized anti IgE anti-
bodies that prevent IgE from interacting with the high-af-
finity portion of the IgE receptor [99]. These drugs prevent 
degranulation of allergen-bound mast cells, which results 
in the release of pro-inflammatory cytokines, including 
IL-4, IL-5, and IL-13, which are associated with airway re-
modeling [100]. anti IgE therapy decreases the level of IgE 
in patients with allergic asthma. It also decreases the num-
ber of inflammatory cells, including mast cells, eosino-
phils, FceRI positive cells, IL-4+ cells, CD3, CD4, and CD8 
T cells in the asthmatic bronchus [101]. Furthermore, anti 
IgE therapy prevents the production of pro-inflammatory 
cytokines and growth factors such as TGF-β [102]. Mark-
ers of inflammation and features of airway remodeling are 
currently being investigated in patients with moderate to 
severe persistent allergic asthma by treatment with omali-
zumab (Clinical Trials.gov identifier: NCT00670930). An 
anti IgE antibody (omalizumab) was approved by the Food 
and Drug Administration (FDA) in 2003 to treat patients 
of greater than 12 years of age with moderate to severe 
persistent allergic asthma. In a recent study on a murine 
model of chronic asthma, anti IgE therapy decreased 
airway inflammation and remodeling features, including 
lung collagen, hydroxyproline, and α-smooth muscle actin 
but did not affect levels of IL-10, TGF-β, or activin A [103]. 
Clinical studies and a few animal studies have shown that 
anti IgE therapy may be a good candidate for relieving 
airway remodeling but may only be applicable to patients 
who suffer from severe allergic asthma correlated with a 
high IgE level.
Anti IL-5 antibody: mepolizumab, reslizumab, enrali-
zumab (MEDI-563)
Mepolizumab is a high-affinity, anti IL-5, humanized 
IgG1 monoclonal antibody that blocks IL-5 binding to 
eosinophils. Based on animal studies, blocking IL-5 may 
be related to improving airway remodeling via eosinophil 
regulation of TGF-β during the remodeling process. This 
antibody was initially evaluated in a group of patients with Cho jy. Recent advances in airway remodeling    375
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mild to moderate asthma and was demonstrated to signifi-
cantly reduce blood eosinophils but did not result in a sig-
nificant improvement in clinical parameters [16]. A study 
on 61 patients found that mepolizumab decreases blood 
and sputum eosinophil levels, prevents further asthma 
exacerbation, and improves asthma-related quality-of-life 
scores [104]. For example, a clinical trial in which mepo-
lizumab was given to patients with asthma for 6 months 
showed reduced exacerbation frequency and steroid re-
quirements [104,105]. Gruenberg and Busse’s study [106] 
suggested that patients who are being treated with steroid 
therapy and continue to have persistent sputum eosino-
philia may benefit from an agent that can specifically tar-
get and reduce eosinophils. Clinical trials with other anti 
IL-5 antibodies, including reslizumab and enralizumab, 
are currently in progress. 
Anti TNF-α: etanercept, infliximab, and golimumab
Etanercept (a soluble form of the recombinant TNF-α 
human receptor) has been used to improve FEV1 scores 
and the quality of life of patients with severe refractory 
asthma [55]. However, a recent phase II clinical study of 
Table 1. Summary of clinical trials for severe asthma
Drug class Compound name Study phase Clinical efficacy and adverse events ClinicalTrials.gov identifier
Anti IgE antibody
a Omalizumab
Xolair
III
IV
Putative add-on therapy for severe persistent 
non-atopic uncontrolled asthma.
Decrease asthma symptoms, asthma exacerba-
tions, and ICS use.
Injection site rashes, headache, GI upsets, 0.2% 
anaphylaxis, concerns for malignancy.
NCT01007149
NCT00252135
Anti IL-5 antibody Mepolizumab  
(SB-240563)
II Reduces exacerbations and ICS use and im-
proves quality of life.
No serious side effects.
Hypotension after infusion.
NCT00292877
TNF-α soluble 
receptor
Etanercept II Increases PC20 and improves the asthma qual-
ity of life score; varied results depending on the 
study.
No serious side effects.
Risk of malignancy, tuberculosis reactivation, 
demyelination, and worsening cardiac failure.
NCT00276029
Anti IL-4Rα antibody AMG 317 II Decreased exacerbations at higher doses, but 
no differences on asthma questionnaires.
No serious side effects reported to date.
NCT00436670
Recombinant hIL-4 
variant
Pitrakinra
(AER 001)
II Reduces asthma-related adverse events.
Small trials.
NCT00535028 and 
NCT00535031
Anti CD25 antibody Daclizumab II Improved FEV1, reduces daytime asthma symp-
toms.
Anaphylactoid reactions, varicella zoster menin-
gitis, breast cancer (3/88). 
NCT00028288
Anti IL-13 antibody CAT-354 II Potentially inhibits TH2 inflammation.
No clinical data available.
NCT00873860
Anti IL-9 antibody MEDI-528 II Potentially decreases TH2 lymphocyte prolifera-
tion and mast-cell recruitment.
No clinical data available.
No serious side effects reported to date.
NCT00968669
Anti TSLP antibody AMG157 I Safety study in healthy subjects and subjects 
with atopic dermatitis.
No data in asthma.
NCT00757042 
NCT00972179
ICS, intermittent corticosteroid; GI, gastrointestinal; IL, interleukin; TNF, tumor necrosis factor; TSLP, thymic stromal lymphopoietin; 
PC20, methecholine provocation concentration 20.
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132 patients with moderate to severe asthma who used 
etanercept for 12 weeks reported no significant difference 
in clinical outcomes between the placebo and treatment 
groups [107]. Even though etanercept is well tolerated, 
doctors and patients should consider the risk/benefit ra-
tio before administration. Some studies have shown that 
the anti TNF-α antibody infliximab significantly reduces 
asthma exacerbation [108]; however, other studies that 
evaluated golimumab, another type of anti TNF-α anti-
body, on 309 patients with severe asthma demonstrated 
no measurable changes in lung function, symptoms, or ex-
acerbation rates in the treatment group [109]. Serious ad-
verse events such as infections and malignancy occurred 
and resulted in early discontinuation. Although TNF-α 
blocking has resulted in promising early results for treat-
ing airway remodeling, its clinical application to asthma 
has been unsuccessful and requires further research to 
continue.
Anti IL-4 antibodies: pascolizumab and Nuvance (IL-4 
receptor antagonists)
IL-4 contributes to the development of asthma by induc-
ing B-cells to switch from the production of IgM to IgE, 
and promotes the aggregation of eosinophils, lympho-
cytes, basophils, and monocytes in target tissues. In addi-
tion, IL-4 mediates differentiation of naïve T-cells into Th2 
cells capable of producing IL-4, IL-5, and IL-13. Nuvance, 
a soluble IL-4 receptor antagonist, improves asthma 
symptoms and reduces FEV1 in patients with moderate to 
severe asthma. However, subsequent studies with a larger 
number of patients did not reproduce the good clinical 
response [110]. Pascolizumab, an anti IL-4 antibody, also 
initially showed promising results, but clinical studies did 
not show favorable results [111]. These negative results 
suggest that IL-4 blocking alone may not be sufficient to 
resolve the allergic inflammation process. 
IL-4 and IL-13 targeted drugs: anti IL4R-α antibody 
(AMG-317), a recombinant human IL-4 variant (pitrakin-
ra)
Receptors for IL-4 and IL-13 are regulated by similar 
signaling pathways. Pitrakinra, a recombinant human 
IL-4 variant, binds to the IL-4 Rα complex and prevents 
binding of both IL-4 and IL-13 [112]. Subcutaneous ad-
ministration of pitrakinra significantly reduces asthma-
related symptoms. In addition, a 12-week study by Corren 
et al. [113] showed that AMG 317, an anti IL-4Rα antibody, 
inhibits the effects of IL-4 and IL-13. They demonstrated 
that the number of asthma exacerbations decreased in the 
higher-dose groups without significant clinical efficacy. 
Therefore, targeting IL-4 and IL-13 together shows a bet-
ter clinical response than IL-4 blocking alone, but larger 
placebo-controlled trials may be needed to demonstrate 
its clinical significance. 
Anti CD25 antibody: daclizumab
CD25 is an IL-2 receptor related to antigen-dependent 
T-cell proliferation and secretion of Th1 and Th2 cytokines 
by activated lymphocytes. Daclizumab is a humanized 
monoclonal antibody that binds to the CD25 α-subunit. 
A 12-week study on 115 patients with moderate to severe 
asthma who received daclizumab demonstrated improve-
ment in FEV1, a decrease in daytime asthma symptoms, 
and a decrease in short-acting β-agonist use [114]. How-
ever, side effects including an anaphylatoid reaction, vari-
cella zoster meningitis, and breast cancer were reported. 
New cytokine targets such as anti IL-9 antibody (Med-
528), anti CD23 antibody (lumiliximab), and anti TSLP 
antibody (AMG 157) have emerged and are now in clinical 
trials. 
 
New pharmacologic targets for airway remodeling 
in asthma (Table 2)
Smooth muscle hypertrophy, hyperplasia, and deposi-
tion of extracellular matrix have been treatment targets 
for airway remodeling. Clinical studies related to new 
drugs, including a c-kit/platelet-derived growth factor 
(PDGF) receptor tyrosine kinase inhibitor (mastinib), an 
endothelin (ET)-1 receptor antagonist (sitaxentan), a cal-
cium channel inhibitor (gallopamil), and statins are now 
being conducted.
c-kit/PDGF receptor tyrosine kinase inhibitor: mastinib
The c-kit/PDGF receptor tyrosine kinase inhibitor ima-
tinib mesylate decreases peribronchial collagen deposition 
and ASM thickening in a murine model of asthma [115]. 
Based on these animal study results, a clinical study eval-
uated the effects of mastinib in a small group of patients 
with severe persistent asthma [116]. Mastinib lowered 
the asthma control questionnaire score and reduced the 
frequency of asthma exacerbations. However, no signifi-
cant improvement in lung function was observed in the Cho jy. Recent advances in airway remodeling    377
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treatment group. Further studies on a larger number of 
patients are needed to determine its efficacy. 
ET-1 receptor antagonist: sitaxentan
ET-1 induces bronchoconstriction, mediates eosinophil 
recruitment during allergic inflammation, and contributes 
to airway remodeling by inducing fibroblast and smooth 
muscle cell differentiation and proliferation [117]. In-
creased ET-1 expression on ASM areas is strongly correlat-
ed with airway obstruction (measured by FEV1) in patients 
with asthma [118]. Another study reported that an ET-1 
receptor polymorphism is strongly associated with the de-
gree of airway obstruction in a population of patients with 
asthma [119]. These data suggest that inhibiting the ET-1 
pathway could be a potential therapeutic option in patients 
with steroid-refractory asthma or an irreversible airway 
obstruction. The ET-1 receptor antagonist sitaxentan is 
now in clinical trials on patients with severe persistent 
asthma.
Calcium channel inhibitor: methoxyverapamil (gallo-
pamil)
Airway remodeling mainly involves increased ASM 
mass, which is related to increased smooth muscle cell 
proliferation. Calcium influx in smooth muscle cells acti-
vates calcium-calmodulin kinase IV (CamK-IV). CamK-IV 
then enhances mitochondrial biogenesis through subse-
quent activation of various transcription factors. In vitro 
studies show that ASM cell proliferation in patients with 
severe asthma is mainly mitochondria-dependent, where-
as that of controls is virtually mitochondria-independent 
[120]. Gallopamil administration induces a reduction in 
mitochondrial mass and subsequent ASM cell prolifera-
tion and is now in clinical trials on patients with severe 
persistent asthma.
HMG-CoA reductase inhibitor: statins-simbastatin, 
atorvastatin, and lovastatin
HMG-CoA reductase inhibitors (statins) are well-known 
cholesterol-lowering agents. Interestingly, they also have 
pleiotropic effects, which include inhibiting ASM cell 
proliferation and promoting ASM cell apoptosis. Despite 
promising in vitro results, two clinical trials have demon-
strated that neither simbastatin [121] nor atrovastatin [122] 
improve inflammatory outcomes and lung function in pa-
tients with allergic asthma. Lovastatin administration in 
patients with severe persistent asthma is now being evalu-
ated for its effects on airway remodeling in clinical trials.
 
Bronchial thermoplasty (BT, Table 3)
BT is a bronchoscopic procedure for patients with severe 
persistent asthma; it delivers thermal energy to the airway 
wall to reduce excess ASM. Preclinical studies have shown 
that BT results in a reduction in ASM and AHR in an 
animal model [123,124]. Initially, a clinical study with 16 
patients confirmed that BT increases the number of mild 
to moderate asthma symptom-free days and the peak ex-
piratory flow rate (PEF) at 3 months, in addition to reduc-
ing AHR for 2 years [125]. In a study of patients with mod-
erate to severe asthma, BT significantly alleviated mild 
exacerbations, reduced the use of reliever medicine, and 
improved morning PEF, resulting in improved asthma-re-
lated questionnaires scores [126]. The recently conducted 
Asthma Intervention Research (AIR) study demonstrated 
Table 2. Summary of clinical trials with new drugs for severe asthma
Drug class Compound name Study phase Clinical efficacy and adverse events ClinicalTrials.gov identifier
c-kit/PDGF receptor 
 kinase inhibitor
Mastinib II Decreases asthma symptoms and frequency 
  of exacerbations
Skin rash, edema, nausea
NCT00842270
Endothelin-1 receptor 
 antagonist
Sitaxentan II Potentially decreases ASM area and 
  submucosal fibroblast count
NCT01050491
Calcium channel  
 inhibitor
Gallopamil (D600) II Abolishes abnormal calcium responses and 
mitochondrial biogenesis in asthmatic ASM 
cells
NCT00896428
Statins Lovastatin II Evaluation of anti-inflammatory effects and 
inhibition of ASM proliferation in severe 
  persistent asthma
NCT00689806
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that BT improves asthma-specific quality of life with a re-
duction in severe exacerbation and healthcare use during 
the post-treatment period in patients with severe asthma 
[127,128]. A long-term (5-year) safety study of BT (AIR 
trial) reported that clinical complications did not increase 
over time, based on the rate of adverse respiratory events. 
It also determined that lung function (FVC and FEV1) had 
not deteriorated over a 5-year period post-BT in patients 
with moderate to severe asthma. These findings suggest 
that BT treatment is a safe procedure with effects that last 
at least 5 years [129]. BT was approved by the FDA in April 
2010 for patients with severe asthma.
 
CONCLUSION
Asthma is a complex disease derived from the inter-
action between inhaled environmental agents and the 
airway. This review focused on recent advances in mecha-
nisms, diagnosis, and treatment of airway remodeling in 
patients with asthma during the last decade. Numerous 
animal studies and clinical trials using biological therapy, 
drugs, and mechanical disruption of airway remodeling 
have been conducted. Acquiring detailed information on 
asthma subtypes for individual patients will help develop 
more specific and effective target treatments for severe 
asthma. Anti IL-5 and anti IgE therapy effectively reduce 
asthma exacerbation in patients with severe asthma. How-
ever, human clinical trials with biological therapy target-
ing individual inflammatory cells and mediators, includ-
ing anti TNF-α and anti IL-4 therapy, have demonstrated 
disappointing results during clinical application. There-
fore, larger studies targeting specific asthma subtypes are 
needed to determine the benefits of each cytokine antago-
nist. Because recent studies have demonstrated that the 
epithelium plays an important role in the initiation of air-
way remodeling, preventing the EMT may be an important 
target for the development of more effective treatments, in 
addition to targeting each cell or mediator. Another can-
didate for severe asthma treatment is to reduce excessive 
ASM with BT. As mechanical disruption of ASM by ther-
mal energy may result in adverse respiratory effects such 
as wheezing, chest discomfort, dyspnea, productive cough, 
and discolored sputum, long-term safety after treatment 
has been an issue. Since recent studies have shown that 
clinical complications did not increase overtime, BT may 
be a safe procedure for severe asthma patients. Over the 
last decade, animal and human studies have provided 
valuable insight into asthma airway remodeling. However, 
many aspects of asthma airway remodeling still remain 
elusive; thus, it is important to further explore the mecha-
nisms of airway remodeling and investigate mediators that 
have the potential to be used as clinical treatments.
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